Skip to main content

Advertisement

Table 1 Clinical and demographic characteristics of the CML patients

From: MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia

Characteristics No. of patients (%)
Total 46 (100%)
Gender
 Female 24 (52.2%)
 Male 22 (47.8%)
Age
 Average 45.2 years
 Range 18–69 years
Phase
 Chronic 29 (63%)
 Accelerated 8 (17.4%)
 Blastic 9 (19.6%)
Sokal Index
 A 11 (23.9%)
 B 13 (28.3%)
 C 19 (41.3%)
 N/A 3 (6.5%)
Response to kinase inhibitor therapy
 Sensitive 17 (37%)
 Resistant 22 (47.8%)
 N/A 7 (15.2%)
  1. N/A not available